Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide

Future Oncology

Volumn 9, Issue 4, 2013, Pages 595-604

  Liu, Dajun ^a   Liu, Ying ^b   Liu, Minghua ^a   Ran, Limei ^c   Li, Yan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Department of Surgery   (China)

^c GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

chemotherapy; hepatic carcinoma; multidrug resistance; parthenolide

Indexed keywords

FLUOROURACIL; I KAPPA B; MULTIDRUG RESISTANCE PROTEIN; PARTHENOLIDE; PROTEIN BCL 2; PROTEIN P53; WNT1 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONCENTRATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; TUMOR SUPPRESSOR PROTEIN P53; WNT1 PROTEIN;

EID: 84875943238     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.15     Document Type: Article

References (28)

1. Shao SL, Zhang WW, Li XY, et al. Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors. Cancer Biother. Radiopharm. 25, 171-177 (2010).
2. Li R, Wu R, Zhao L, et al. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 4, 1399-1408 (2010).
3. Squatrito M, Brennan CW, Helmy K, et al. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619-629 (2010).
4. Dai M, Luo R, Zhong H, et al. Establish and biological activity of human lung adenocarcinoma cell line of taxol resistance. J. Pract. Med. 23, 2826-2829 (2007).
5. Wakamatsu T, Nakahashi Y, Hachimine D, et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int. J. Oncol. 31(6), 1465-1472 (2007).
6. Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14, 584-596 (2009).
7. Venkatesan B, Prabhu SD, Venkatachalam K, et al. WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal 22, 809-820 (2010).
8. Wei W, Chua MS, Grepper S, et al. Blockade of Wnt1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol. Cancer 8, 76 (2009).
9. Li Y, Li Y, Niu X, et al. Synthesis and antitumor activity of a new mixed-ligand complex di-n-butyl- (4-chlorobenzohydroxamato)tin(IV) chloride. J. Inorg. Biochem. 102, 1731-1735 (2008).
10. Goda K, Bacsó Z, Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr. Cancer Drug Targets 9, 281-297 (2009).
11. Lian Z, Niwa K, Gao J, et al. Association of cellular apoptosis with anti-tumor effects of the Chinese herbal complex in endocrine-resistant cancer cell line. Cancer Detect. Prev. 27, 147-154 (2003). (Pubitemid 36429595)
12. Tan W, Lu J, Huang M, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin. Med. 6, 27 (2011).
13. Oka D, Nishimura K, Shiba M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int. J. Cancer 120, 2576-2581 (2007). (Pubitemid 46651277)
14. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide dependent proapoptotic activity in cancer cells. Folia Histochem. Cytobiol. 46, 129-135 (2008).
15. Shanmugam R, Jayaprakasan V, Gokmen- Polar Y, et al. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 66, 1498-1511 (2006). (Pubitemid 44465816)
16. Ralstin MC, Gage EA, Yip-Schneider MT, et al. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol. Cancer Res. 4, 387-399 (2006). (Pubitemid 44035158)
17. Wu C, Chen F, Rushing JW, et al. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J. Med. Food 9, 55-61 (2006). (Pubitemid 44153618)
18. Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther. 4, 587-594 (2005). (Pubitemid 40601840)
19. Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide dependent proapoptotic activity in cancer cells. Folia Histochem. Cytobiol. 46, 129-135 (2008).
20. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev. Anticancer Ther. 7, 369-378 (2007).
21. Wang S, Yang C. Research progress of the cancer chemotherapy drug-induced apoptosis. Chin. J. Cancer 19, L173-L176 (2007).
22. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 12, 55-64 (2009).
23. Xu HW, Xu L, Hao JH, et al. Expression of P-glycoprotein and multidrug resistance associated protein is associated with multidrug resistance in gastric cancer. J. Int. Med. Res. 38, 34-42 (2010).
24. Kim YI, Kim BH, Khang I, et al. Cell growth regulation through apotosis by activin in human gastric cancer SNU-16 cell lines. Oncol. Rep. 21, 491-497 (2009).
25. Kim YC, Clark RJ, Ranheim EA, Alexander CM. Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell autonomous beta catenin effector. Cancer Res. 68, 10145-10153 (2008).
26. Chen J, Ouyang ZG, Zhang SH, et al. Down regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncol. Rep. 17, 1445-1451 (2007).
27. Tan X, Behari J, Cieply B, et al. Conditional deletion of b-catenin reveals its role in liver growth and regeneration. Gastroenterology 131, 1561-1572 (2006). (Pubitemid 44708943)
28. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007). (Pubitemid 46232886)